The Relationship of CYFRA 21-1 to the Metastatic Process of Advanced Non- Small Cell Lung Carcinoma

Lung cancer is a leading cause of death worldwide. Globally, lung cancer is estimated to cause 2.2 million new cases and 1.8 million deaths in 2020. About 85% of total lung cancer cases are estimated to be Non-Small Cell Carcinoma Lung Cancer (NSCLC). Lung cancer itself has several tumor markers because the type of cancer depends on its cell origin where Cytokeratin19 fragment (CYFRA 21-1) is used for squamous cell carcinoma type lung cancer. This study aims to assess the sensitivity of CYFRA 21-1 tumor biomarker examination in advanced non-small cell carcinoma lung cancer. This study was a cross-sectional study in lung cancer patients at Wahidin Sudirohusodo Hospital in the period January- March 2023. Each research subject collected bronchial lavage and serum samples, then tested CYFRA 21-1 levels using the ELISA method. The results showed that in subjects with JPBSK, most diagnoses were made based on the bronchial lavage method (72.7%), diagnosed at an advanced stage (88.5%) with a cytology/histology type of squamous cell carcinoma (43.2%). The research data showed that the serum level of CYFRA 21-1 in NSCLC patients was higher than non-cancer patients (p=0.015). It can be concluded that serum CYFRA 21-1 levels increased significantly in NSCLC subjects when compared to non-cancer. Keywords: NSCLC, CYFRA 21-1, Bronchial Rinses, Serum